How did immune checkpoint inhibitors and CAR T-cell therapy advance cancer immunotherapy?

In the context of translational medicine, which coordinates laboratory research with clinical practice, immune checkpoint inhibitors (ICIs) and CAR T-cell therapy have revolutionized cancer treatment by harnessing the immune system to target malignant cells.12

Immune Checkpoint Inhibitors

ICIs function by blocking proteins—such as CTLA-4, PD-1, and PD-L1—that normally act as "brakes" on the immune system. By abolishing these inhibitory signals, ICIs allow T cells to recognize and destroy cancer cells that would otherwise evade detection. Since the 2011 approval of ipilimumab, these therapies have shifted oncology goals toward long-term survival for patients with various advanced cancers.314

CAR T-Cell Therapy

CAR T-cell therapy involves genetic engineering to modify a patient's own T cells. By inserting a gene for a chimeric antigen receptor, these cells are programmed to identify and bind to specific antigens on cancer cells. Once infused back into the patient, these engineered cells proliferate and mount a targeted attack. Since its 2017 approval, this approach has proven highly effective for certain blood cancers, often inducing complete remission in relapsed or refractory cases.54